Posted by Michael Wonder on 21 May 2020
Chiesi Group receives FDA approval for Ferriprox (deferiprone) twice-a-day tablets
21 May 2020 - Chiesi Global Rare Diseases today announced that the U.S. FDA has approved Ferriprox (deferiprone) twice-a-day tablets for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
The new formulation of twice-a-day Ferriprox 1000 mg oral tablets eliminates the mid-day dose.
